ANNX: Annexon Company Short-Term Debt

Official company branding of annexonbio.com (ANNX)

Annexon, Inc. (ANNX) specializes in developing innovative drugs to combat neurodegenerative pathologies. The business relies on an autonomous production cycle that remains independent of global economic fluctuations, ensuring the asset's stability. This price chart on the GURU.Markets platform captures the 0.00 metric, while the company expands its pipeline of drugs that block immune proteins for the therapy of rare brain and vision impairments.

ANNX (Annexon) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for Annexon Biosciences Inc. (ANNX)

- current quotes and average value forecast:
Price Chart Annexon|ANNX - Fair Value Consensus
- market capitalization information:
Market Value Annexon Biosciences|ANNX - Total Enterprise Value
- shareholders' equity book value data:
Book Value per Share Annexon|ANNX - Book Capitalization|Market Value to Book Value Ratio annexonbio.com|ANNX - Total Business Assets
- debt and liquidity details:
Debt to Equity Annexon, Inc.|ANNX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Annexon, Inc.|ANNX - Company Cumulative Debt|Debt to Book Value Annexon Biosciences|ANNX - Company Long-Term Indebtedness|Company Short-Term Debt Annexon|Quick Liquidity annexonbio.com
- net income and valuation multiples indicators:
ANNX - Company Profit
Basic company analysis:Annexon - ANNX
Mass-produced product of Annexon Biosciences Inc.

The long-term reliability of Annexon, Inc. (ANNX) is determined by the issuer's ability to service current liabilities without liquidity risk. This metric aggregates all debts with maturities of up to twelve months, identifying potential cash gaps. By analyzing the short-term debt profile, an investor assesses the balance between financial stability and capital efficiency. Minimizing these liabilities is critical during the large-scale implementation of robotic antibody screening systems. Laboratory automation requires significant capital expenditures that must not burden the company's operating budget.

Direct competitors

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|ACAD (ACADIA Pharmaceuticals) - Company Short-Term Debts|Company Short-Term Debts xenon-pharma.com|Company Short-Term Debt Viking Therapeutics, Inc. (VKTX)|Supernus Pharmaceuticals, Inc. - Company Short-Term Indebtedness|Company Short-Term Debt Catalyst Pharmaceuticals Inc CPRX|DNLI: Company Short-Term Indebtedness|Harmony Biosciences - Company Short-Term Debts|Short-Term Debt biohavenpharma.com|AMLX (Amylyx Pharmaceuticals, Inc.) - Company Current Liabilities|Company Short-Term Indebtedness TRVI|Company Short-Term Debt Praxis Medicines|Short-Term Debt Anavex Life Sciences Corp AVXL|Company Short-Term Debt CeriBell, Inc. (CBLL)|Prothena Corporation plc - Company Short-Term Indebtedness|Alector - Company Current Liabilities|Company Short-Term Loans and Borrowings OMER|Neurogene Corp - Company Short-Term Debts|Short-Term Debt Volume AC Immune Inc ACIU|Voyager Therapeutics (VYGR) - Company Short-Term Debt|Company Short-Term Indebtedness NMRA|SCLX (Scilex) - Company Short-Term Debts|Company Current Liabilities Tevogen Bio Holdings Inc. (TVGN)|Company Current Liabilities ACOG (Alpha Cognition)|Short-Term Debt Volume cogrx.com|Company Short-Term Debts IKT (Inhibikase Therapeutics)|Company Short-Term Debts cassavasciences.com SAVA|ASRT - Company Short-Term Debt|COYA (Coya Therapeutics, Inc.) - Company Short-Term Indebtedness|vistagen.com (VTGN) - Company Short-Term Debt|Company Short-Term Indebtedness OVID|Company Current Liabilities ABOS|Company Short-Term Indebtedness CRVO (cervomed.com)|Company Short-Term Debt Alterity Therapeutics (ATHE)|clene.com - Company Short-Term Indebtedness|Company Short-Term Debts PEPG (PepGen)|jupiterneurosciences.com (JUNS) - Short-Term Debt|RLMD: Company Current Liabilities|ANVS - Company Short-Term Debts|gracetx.com (GRCE) - Company Short-Term Debt|Firefly Neuroscience, Inc. - Company Short-Term Loans and Borrowings|Company Short-Term Debt ANEW Medical|Short-Term Debt NeuroSense Therapeutics, Ltd. NRSN|Company Short-Term Debts RVPH|Company Short-Term Debts metaviatx.com (MTVA)|Company Short-Term Debt NeurAxis NRXS|HSDT: Company Short-Term Indebtedness|PASG - Company Short-Term Debt|NEUP (Neuphoria Therapeutics Inc.) - Company Short-Term Indebtedness|NERV: Company Short-Term Debts|Short-Term Debt athira.com (ATHA)|Company Current Liabilities ADXN|Company Short-Term Indebtedness ALZN (Alzamend)|Company Short-Term Debt Cyclerion Therapeutics (CYCN)|PTIX - Short-Term Debt|Company Short-Term Debt Pasithea Therapeutics Corp. KTTA|CRGT: Company Short-Term Indebtedness|ATXI: Company Current Liabilities|Company Short-Term Loans and Borrowings BCLI (Brainstorm Cell Therapeutics Inc.)|CARA: Company Short-Term Debts|CHRO - Short-Term Debt Volume|Company Short-Term Debt Eliem Therapeutics, Inc.|Company Short-Term Indebtedness ITCI (Intra-Cellular)|Company Short-Term Debts LBPH|Company Current Liabilities Marinus Pharmaceuticals Inc MRNS|NKGen - Company Current Liabilities|Short-Term Debt Volume NeuroBo Pharma (NRBO)|Sage Therapeutics, Inc. - Company Short-Term Debts|SNPX - Company Short-Term Debts|Trevena (TRVN) - Company Short-Term Debt|Company Short-Term Indebtedness VIGL|Company Short-Term Debt Anew Medical, Inc.|Company Short-Term Indebtedness CERE (Cerevel Corp)